PRELUDE THERAPEUTICS INC
PRLDNASDAQTrading Snapshot
- Day Range
- $5.39 – $5.52
- 52-Week Range
- $0.75 – $5.69
- Volume
- $3.42B
- Avg Volume
- $3.77B
- Shares Outstanding
- 79.7M
- Next Earnings
- Oct 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $12M
- Last Q Revenue
- $6M
- P/E Ratio
- —
- P/S Ratio
- 23.0x
- EPS (TTM)
- $-0.59
- Dividend Yield
- —
Why Investors Own PRLD
- ✓High-growth profile — revenue up +3.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PRELUDE THERAPEUTICS INC
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704M
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 65.85 percent increase over losses of $(0.41) per share
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $8 price target.
Which stocks are gapping on Tuesday?
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Which stocks are moving before the opening bell on Tuesday?
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting better-than-expected earnings and raising FY26 guidance.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD) shares moved